| A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma (NCT00647101) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-12-01 |
| Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan (NCT00121147) | Hermann Eye Center | 2003-09-01 |
| Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients (NCT00069706) | Alcon Research | 2003-07-01 |
| Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension (NCT00652106) | Allergan | 2003-06-01 |
| Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh. (NCT00143208) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-05-01 |
| Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension (NCT00652483) | Allergan | 2003-05-01 |
| Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension (NCT00332059) | Allergan | 2003-05-01 |
| Study of TRAVATAN in Subjects With Iris Pigmentation Changes (NCT00047554) | Alcon Research | 2003-05-01 |
| Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension (NCT00061503) | Alcon Research | 2003-04-01 |
| A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension (NCT00061529) | Alcon Research | 2003-01-01 |
| A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension (NCT00311389) | Alcon Research | 2003-01-01 |
| Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension (NCT00061516) | Alcon Research | 2003-01-01 |
| Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension (NCT00061542) | Alcon Research | 2003-01-01 |
| A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension (NCT01379144) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-01-01 |
| Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension (NCT00651859) | Allergan | 2002-11-01 |
| Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32 (NCT00047606) | Alcon Research | 2002-08-01 |
| A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension (NCT00150267) | Pfizer | 2002-02-01 |
| Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. (NCT00140062) | Pfizer | 2002-02-01 |
| Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (NCT00847483) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2002-01-01 |
| 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension (NCT01655758) | University of Parma | 2002-01-01 |
| Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension (NCT00332072) | Allergan | 2001-08-01 |
| Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension (NCT00332540) | Allergan | 2001-08-01 |
| Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70 (NCT00047541) | Alcon Research | 2001-02-01 |
| A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) (NCT00051142) | Alcon Research | 2001-02-01 |
| Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69 (NCT00047515) | Alcon Research | 2001-01-01 |
| A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT) (NCT00051155) | Alcon Research | 2001-01-01 |
| Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41 (NCT00047528) | Alcon Research | 2001-01-01 |
| The International Collaborative Exfoliation Syndrome Treatment Study (NCT00804115) | The New York Eye & Ear Infirmary | 2000-08-01 |
| Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom (NCT01012245) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2000-01-01 |
| Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension (NCT00332384) | Allergan | 2000-01-01 |
| A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma (NCT00051181) | Alcon Research | 2000-01-01 |
| Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98 (NCT00047593) | Alcon Research | 2000-01-01 |
| Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension (NCT00332436) | Allergan | 1999-12-01 |
| Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension (NCT00332345) | Allergan | 1999-07-01 |
| Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients (NCT00069719) | Alcon Research | 1999-02-01 |
| Early Diagnosis, Pathogenesis and Progression of Open Angle Glaucoma (NCT00494923) | University of Erlangen-Nürnberg Medical School | 1999-01-01 |
| A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients (NCT00856622) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 1997-08-01 |
| Ocular Hypertension Treatment Study (OHTS) (NCT00000125) | Washington University School of Medicine | 1994-02-01 |
| Ocular Hypertension Treatment Study (OHTS) (NCT00803998) | The New York Eye & Ear Infirmary | 1994-02-01 |
| A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension (NCT00751127) | Pfizer | 1993-01-01 |
| A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom (NCT00751049) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 1992-12-01 |
| A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia (NCT00751062) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 1992-11-01 |
| Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens (NCT00001161) | National Eye Institute (NEI) | 1977-07-01 |
| Pigment Dispersion Syndrome With and Without Glaucoma (NCT00001152) | National Eye Institute (NEI) | 1976-06-01 |
| Corneal Versus Conjunctival Delivery Using a Delivery Device (NCT00143429) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Bimatoprost Versus Travoprost at Cairo University (NCT01092273) | Cairo University | |
| Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension (NCT00657579) | Santen Pharmaceutical Co., Ltd. | |
| To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension (NCT00656240) | Santen Pharmaceutical Co., Ltd. | |
| Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device (NCT00283764) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |